

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Public attitudes towards healthcare measures promoting tobacco cessation in Germany: results from the representative German Study on Tobacco Use (the DEBRA study)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026245
Article Type:	Research
Date Submitted by the Author:	27-Aug-2018
Complete List of Authors:	Kastaun, Sabrina; Heinrich-Heine-University, Düsseldorf, Institute of General Practice, Addiction Research and Clinical Epidemiology Unit Kotz, Daniel; Heinrich-Heine-University Duesseldorf, Institute of General Practice, Addiction Research and Clinical Epidemiology Unit; University College London, Department of Behavioural Science and Health Brown, Jamie; University College London, Department of Behavioural Science and Health Shahab, Lion; University College London, Department of Behavioural Science and Health Boeckmann, Melanie; Medical Faculty of the Heinrich-Heine-University, Institute of General Practice
Keywords:	PUBLIC HEALTH, EPIDEMIOLOGY, PRIMARY CARE

SCHOLARONE™  
Manuscripts

Only

1  
2  
3 **Public attitudes towards healthcare measures promoting tobacco cessation in Germany:**  
4 **results from the representative German Study on Tobacco Use (the DEBRA study)**  
5

6 Sabrina Kastaun<sup>1\*</sup>, Daniel Kotz<sup>1,2</sup>, Jamie Brown<sup>2</sup>, Lion Shahab<sup>2</sup>, Melanie Boeckmann<sup>1</sup>  
7  
8  
9

10  
11 <sup>1</sup>Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of  
12 the Heinrich-Heine-University, Düsseldorf, Germany  
13

14  
15 <sup>2</sup>Department of Behavioural Science and Health, University College London, London, UK  
16  
17

18  
19  
20 **\*Correspondence**  
21

22 Dr. Sabrina Kastaun, Institute of General Practice, Addiction Research and Clinical Epidemiology Unit,  
23 Medical Faculty of the Heinrich-Heine-University Düsseldorf, Werdener Str. 4, 40227 Düsseldorf,  
24 Germany, Tel: 0049-211-81-19527, Mail: [Sabrina.Kastaun@med.uni-duesseldorf.de](mailto:Sabrina.Kastaun@med.uni-duesseldorf.de), Website:  
25 [www.debra-study.info](http://www.debra-study.info).  
26  
27

28  
29  
30 **Email co-authors**

31 Daniel Kotz: [daniel.kotz@med.uni-duesseldorf.de](mailto:daniel.kotz@med.uni-duesseldorf.de)

32 Jamie Brown: [jamiebrown10@gmail.com](mailto:jamiebrown10@gmail.com)

33 Lion Shahab: [lion.shahab@ucl.ac.uk](mailto:lion.shahab@ucl.ac.uk)

34 Melanie Boeckmann: [melanie.boeckmann@med.uni-duesseldorf.de](mailto:melanie.boeckmann@med.uni-duesseldorf.de)  
35  
36  
37

38  
39  
40  
41 **Manuscript word count:**

42 Main text: 3,264 (excluded: title page, abstract, references, tables, declarations)  
43

44 Abstract: 253 words  
45

46 Tables: 3  
47

48 Figures: 2  
49

50 Supplementary files: 1  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

### Objective

The aim of this study was to assess public acceptance of four possible healthcare measures supporting tobacco dependence treatment in Germany.

### Design

Cross-sectional household survey.

### Setting

Data were drawn from the German population and collected through computer-assisted, face-to-face interviews.

### Participants

Representative random sample of 2,087 people ( $\leq 14$  years) of the German population.

### Outcome measures

Public acceptance was measured regarding treatment cost reimbursement, standard training on offering cessation treatment for health professionals, and making cessation treatment a standard part of care for smokers with physical or mental disorders. Associations with smoking status and socio-economic (SES) characteristics were assessed.

### Results

Support for all measures was high (50%-68%), even among smokers (48%-66%). Ex- or never-smokers were more likely to support standard training on cessation for health professionals than current smokers (OR 1.43, 95%CI 1.07–1.92; OR 1.43; 95%CI 1.14–1.79, respectively). Ex-smokers were also more likely than current smokers to support cessation treatment for smokers with mental disorders (OR 1.39, 95%CI 1.11–1.73). Men were less likely than women to support cessation treatment for smokers with physical diseases (OR 0.74, 95%CI 0.60–0.91) and free provision of treatment (OR 0.80, 95%CI 0.66–0.97). Offering cessation treatment was generally more accepted to smokers with physical rather than mental disorders.

### Conclusions

The majority of the German population supports healthcare measures to improve the availability and affordability of tobacco dependence treatment. Non-smokers were more supportive than current

1  
2  
3 smokers of two of the four policies, but odds of support were only about 40% greater. SES  
4 characteristics were not consistently associated with public acceptance.  
5

6  
7 **Trial registration number**

8  
9 [DRKS00011322](https://www.drks.de/DRKS00011322)  
10  
11  
12

13  
14 **Strengths and limitations of this study**  
15

- 16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37
- This is the first study helping to fill a knowledge gap on what changes to the tobacco cessation treatment system in Germany the country's population would agree to.
  - Data was obtained from a sample which is representative for the German population.
  - Analysis takes into account sociodemographic and socioeconomic factors as well as smoking status of the respondents.
  - Since assessed measures are only hypothetical, we are unable to say whether public support would change in light of actual implementation.
  - It would also be important to gain insight into the healthcare professionals' perspective regarding the support towards healthcare measures promoting tobacco cessation in Germany

38  
39 **Key words**

40 Healthcare measures, Public opinion, Smoking cessation, Household Survey  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Treating tobacco use is a major public health issue: smoking remains a leading cause of death, killing approximately 6 million people worldwide each year.<sup>1</sup> Compared with other Western European countries, e.g. the Netherlands (19%), England (17%), or Sweden (7%),<sup>2</sup> the prevalence of tobacco smoking in Germany remains high (28%).<sup>3</sup> Moreover, smoking is unequally distributed across different socioeconomic groups within the population, with higher rates of smoking in more disadvantaged groups.<sup>3, 4</sup> Hence, interventions to reduce tobacco consumption should also aim to decrease tobacco-related health inequalities, and smoking cessation treatment as part of health services should be equally accessible to all social groups.

Article 14 of the World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC) [1] states that ratifying countries should take effective measures to promote cessation of tobacco use and provide adequate treatment for tobacco dependence.<sup>5</sup> To assist countries in fulfilling these obligations, guidelines for the implementation of Article 14 of the WHO FCTC have been developed,<sup>5</sup> proposing the following healthcare measures to reduce national smoking prevalence: integrating brief advice to quit smoking into all health-care systems; ensuring that all health care workers are trained to provide brief smoking cessation support to their smoking patients; using existing health infrastructures for access to tobacco cessation (including primary care); and making evidence-based smoking cessation medication available to all smokers wanting to quit, either freely or at least at an affordable cost.

Whereas other European countries that ratified the FCTC made substantial progress to put these healthcare measures into practice, the level of implementation in Germany is comparably poor. In England, for example, a country with exemplary tobacco control,<sup>6</sup> smokers can easily access country-wide Stop Smoking Services to receive behavioural support and pharmacotherapy for free.<sup>7</sup> The National Centre for Smoking Cessation and Training (NCSCCT) offers an online brief advice module to healthcare professionals for free, which has been completed by about 40,000 healthcare professionals to date.<sup>8</sup> Moreover, a national payment for performance system, the Quality and Outcomes Framework (QOF), was introduced in England in 2004 to improve the quality of primary care for patients,<sup>9</sup> and for secondary care in 2017.<sup>10</sup> Regarding the care for smoking patients with and without chronic diseases, the QOF rewards general practitioners (GPs) financially for delivering specific evidence-based interventions: e.g., recording their patients' smoking status, providing brief smoking cessation advice, and offering evidence-based smoking cessation treatment.<sup>9</sup>

In Germany, evidence-based treatments are still not, or only partly, reimbursed and stop-smoking services rarely exist. According to national clinical guidelines, evidence-based cessation methods and

1  
2  
3 brief advice to quit tobacco should be routinely offered to smoking patients in medical and  
4 psychosocial healthcare settings.<sup>11,12</sup> However, GPs lack training in smoking cessation promotion as  
5 training is not a standard part of medical education, and to date no specific reimbursement is  
6 provided to GPs for offering brief smoking cessation counselling.<sup>13</sup>  
7  
8

9  
10 As a consequence, less than 20% of smokers in Germany visiting their GP in the past year report  
11 receiving brief smoking cessation counselling,<sup>14</sup> which contrasts with England where half of all  
12 smokers report having received counselling.<sup>15</sup> The majority (> 80%) of smokers in Germany still try to  
13 quit unaided or with the use of non-evidence-based treatments,<sup>3</sup> and thus limit their chances of  
14 success.<sup>16</sup> Hence, there is an urgent need to improve implementation of Article 14 FCTC in German  
15 healthcare.  
16  
17

18  
19 Implementation of healthcare measures tackling smoking prevalence at population level can only be  
20 successful if it is broadly accepted by the public and used by those affected. However, little is  
21 currently known about public support for healthcare measures to reduce tobacco-related health  
22 effects in Germany. The few existing studies focus exclusively on public attitudes towards tobacco  
23 control measures such as increasing taxes, improving public education, and environmental  
24 restrictions.<sup>17-19</sup>  
25  
26  
27  
28

29  
30 Appropriate data are needed to improve the understanding of structural possibilities for the  
31 implementation of measures in German healthcare. Implementation usually requires political will,  
32 which often relies on understanding the level of public support. The German Study on Tobacco Use  
33 (DEBRA), an ongoing national representative survey, provides such data.  
34  
35  
36

### 37 **Objective**

38  
39 The aim of this study was to assess public support for possible legislative changes on healthcare  
40 measures that, according to Article 14 WHO FCTC, should have long been implemented in German  
41 healthcare.  
42  
43  
44  
45  
46

### 47 **METHODS**

#### 48 **Design, setting, and participants**

49  
50 Data on public support for the implementation of potential healthcare measures were collected as  
51 part of the nationally representative DEBRA study ("DEutsche Befragung zum RAuchverhalten",  
52 [www.debra-study.info](http://www.debra-study.info)). DEBRA started in June 2016 and consists of cross-sectional, computer-  
53 assisted household interviews in people aged 14 years and older, carried out by a market research  
54  
55  
56  
57  
58  
59

1  
2  
3 institute as part of a larger omnibus survey. Over a period of at least 3 years, a new representative  
4 sample of approximately 2,000 respondents of the German population will complete the survey  
5 every two months. Beyond smoking status, smoking and quitting behaviour, use of cessation  
6 methods and of electronic cigarettes, respondents report on socio-demographic characteristics.  
7 Methodological details, including details of the sampling approach, as well as the complete DEBRA  
8 questionnaire have been published in the study protocol.<sup>20</sup> The study was conducted in accordance  
9 with the Declaration of Helsinki, and the protocol of this study has been peer-reviewed and approved  
10 by the ethics committee of the Heinrich-Heine-University Duesseldorf, Germany (ID 5386/R).  
11  
12  
13  
14  
15

16 Questions on public support for specific policies were asked during wave 2 of the study in  
17 August/September 2016, in a total sample of 2,087 respondents. For this wave, questions on public  
18 acceptance towards a) tobacco control strategies and b) healthcare policy measures were included.  
19 Findings on legislative tobacco control strategies such as a total ban of tobacco products or raising  
20 the legal age for tobacco consumption have been published elsewhere.<sup>21</sup> This article discusses  
21 findings of the questions on public attitudes towards healthcare measures suggested in Article 14 of  
22 the WHO FCTC.  
23  
24  
25  
26  
27  
28  
29

## 30 **Measures**

### 31 *Socio-demographic and smoking characteristics*

32  
33  
34  
35 Socio-demographic data on age, sex, education and net household income from all respondents are  
36 routinely collected in the omnibus survey by the market research institute. In the current analysis,  
37 level of education of every respondent was categorised from highest to lowest as 5 = high school  
38 equivalent ("Allgemeine Hochschulreife"), 4 = advanced technical college equivalent  
39 ("Fachhochschulreife"), 3 = secondary school equivalent ("Realschulabschluss"), 2 = junior high  
40 school equivalent ("Hauptschulabschluss"), and as 1 = no qualification. Respondents provided a point  
41 estimate of their net household income, which was categorised into 6 = more than 5000€/month, 5 =  
42 4000- less than 5000€/month, 3 = 2000 - less than 3000€/month, 4 = 3000 - less than 4000€/month,  
43 2 = 1000- less than 2000€/month, and 1 = less than 1000€/month. Respondents were categorised as  
44 current tobacco smokers (cigarettes or other tobacco products), as ex-smokers if they had stopped  
45 during the past year or more than a year ago, or as never smokers if they had never smoked for a  
46 year or longer.  
47  
48  
49  
50  
51  
52  
53

54 Current smokers of tobacco products were asked further details on their smoking behaviour: number  
55 of cigarettes smoked per day (answers per week or month were converted for analyses), about their  
56  
57  
58  
59  
60



1  
2  
3 current motivation to quit smoking using the translated and culturally adapted German version of  
4 the Motivation to Stop Smoking Scale,<sup>22</sup> and whether or not they made at least one quit attempt  
5 during the past year.  
6  
7  
8  
9

### 10 *Measures of public support*

11  
12 Public support was assessed with four suggestions on potential healthcare measures related to  
13 tobacco cessation. These suggestions have been adapted from the Smoking Toolkit Study (STS),<sup>23</sup> a  
14 methodologically comparable household survey, allowing comparisons with data from England at a  
15 later stage.  
16  
17  
18

19  
20 Participants were asked whether they would (a) “strongly support”, (b) “tend to support”, (c) “have  
21 no opinion either way”, (d) “tend to oppose”, (e) “strongly oppose”, or (f) “don’t want to answer” the  
22 four statements listed below. Answers are classified into “agree” (a and b), “disagree” (d and e),  
23 “undecided” (c) and “no answer” (f), and further dichotomised for the regression analyses into  
24 “agree” (a and b) and “don’t agree” (c, d and e), with those responding ‘f’ excluded.  
25  
26  
27

- 28 1. “Every smoker who wants should get support that is clinically proven to help stop smoking, and  
29 costs for these treatments (pharmacological or behavioural smoking cessation therapy) should be  
30 reimbursed”.
- 31 2. “Making sure that all healthcare professionals directly involved in the treatment or care of  
32 patients are trained to advise smokers on how to stop smoking”.
- 33 3. “Making stop-smoking support a standard part of care for smokers with long-term physical health  
34 problems (such as cardiovascular or respiratory diseases)”.
- 35 4. “Making stop-smoking support a standard part of care for smokers with mental health problems  
36 (such as depression or schizophrenia)”.
- 37  
38  
39  
40  
41  
42  
43  
44

45  
46 Statements were asked in a random order to avoid primacy and recency effects.<sup>24</sup>  
47  
48  
49

### 50 **Data analysis**

51  
52  
53 Descriptive analyses using unweighted data were carried out to characterise the total sample as well  
54 as the subsamples according to smoking status of respondents. For categorical variables, proportions  
55  
56  
57  
58  
59

1  
2  
3 were computed and for continuous variables, data were presented in terms of means and standard  
4 deviations (SD).  
5

6  
7 To provide prevalence data on public support for potential healthcare policies, the sample was  
8 weighted to be representative of the German population. Details on weighting procedures have been  
9 published in the study protocol.<sup>20</sup>  
10

11  
12 Associations between support of suggested healthcare measures and sample characteristics and, in  
13 current smokers, smoking characteristics were assessed with exploratory multivariable logistic  
14 regression analyses using unweighted data (dichotomous dependent variable “agree on a potential  
15 healthcare policy measure” (yes vs.no)). Sample characteristics included in the model were sex, age,  
16 net household income, education, and smoking status. For the subgroup analysis in current smokers,  
17 the following smoking characteristics were also included: number of cigarettes smoked per day,  
18 current motivation to stop smoking,<sup>22</sup> and attempts to quit smoking (any vs. none) during the past  
19 year. To assess whether the sub-sample of smokers differed from the sub-sample of non- and ex-  
20 smokers, we ran the regression model for the latter group separately (Supplementary Table 1).  
21  
22  
23  
24  
25

26  
27 Out of the total sample, 25 respondents (1.1% of the total sample) refused to disclose their smoking  
28 status and were thus excluded from all analyses. Respondents who refused to answer questions on  
29 either their educational level, their attempts to quit smoking, or on questions regarding their support  
30 for potential healthcare policies were only excluded from the multivariate logistic regression analyses  
31 (statement 1 = 177 missing (8.6%), statement 2 = 187 missing (9.1%), statement 3 = 179 missing  
32 (8.7%), and statement 4 = 245 missing (11.9%)).  
33  
34  
35  
36  
37  
38  
39

## 40 RESULTS

### 41 Sample characteristics

42  
43 Unweighted baseline characteristics of the analysed sample of 2,062 respondents with full data on  
44 their smoking status are presented in **Table 1**. The sample had a mean age of 51.8 years (standard  
45 deviation [SD] =  $\pm$  20 years), and 1,070 (51.9%) of the respondents were female. In total, 1,107  
46 (53.7%, 95% confidence interval [CI] = 51%-55%) respondents were never smokers, 369 (17.9%,  
47 95%CI = 16%-19%) were ex-smokers, and 586 (28.4%, 95%CI = 26%-30%; unweighted) were current  
48 smokers. **Table 2** presents data on smoking characteristics for this subsample of current smokers.  
49  
50  
51  
52  
53  
54

### 55 Public support for healthcare measures

1  
2  
3 **Figure 1** presents rates of support for suggested healthcare measures, weighted to be representative  
4 for the German population. All four measures receive support from the majority of the population.  
5 Of the total sample, 52% (95%CI = 50%-55%) agreed to providing cessation support to every smoker  
6 for free, 62% (95%CI = 60%-64%) would support standard training on cessation for health  
7 professionals, 68% (95%CI = 66%-70%) would support cessation as standard care for patients with  
8 chronic physical diseases, and half of the sample (50%, 95%CI = 47%-51%) supports cessation for  
9 patients with mental disorders.  
10  
11  
12  
13

14 Among the subsample of current smokers (**Figure 2**), the majority also agreed with all four healthcare  
15 measures, with standard cessation provision for patients with physical comorbidities again ranking  
16 highest at 66% (95%CI = 62%-70%). Slightly fewer smokers (54%, 95%CI = 50%-58%) than in the total  
17 sample would support standard training for all health professionals.  
18  
19  
20  
21

### 22 **Factors associated with public support**

23  
24 **Table 3** presents the results of the multivariable logistic regression for the suggested healthcare  
25 measures for the total unweighted sample, and for the subgroup of current smokers (for the sake of  
26 completeness we ran the regression model again for the group of non- and ex-smokers, please see  
27 Supplementary Table 1). Overall, socio-demographic and smoking characteristics are not consistently  
28 associated with support for proposed healthcare measures, with the exception of sex and smoking  
29 status.  
30  
31  
32  
33

34 Men had lower odds of agreeing with **free provision of cessation treatment** (OR 0.80, 95%CI 0.66 –  
35 0.97) than women. Household income showed no significant associations with support for the  
36 measure, while those with education levels of junior high school equivalent to advanced technical  
37 college equivalent had higher odds of supporting free provision (OR 1.36, 95%CI 1.03-1.79; OR 1.34,  
38 95%CI 1.05-1.72, OR 1.50, 95%CI 1.00-2.24).  
39  
40  
41  
42

43 Standard **training of health professionals** in cessation had higher odds of being supported by ex- or  
44 never-smokers (OR 1.43, 95%CI 1.07-1.92 and OR 1.43, 95%CI 1.14-1.79, respectively) than current  
45 smokers.  
46  
47

48 Men were less likely than women to support **cessation as standard care for patients with physical**  
49 **diseases** (OR 0.74, 95%CI 0.60-0.91).  
50  
51

52 Regarding **cessation as standard care for patients with mental illness**, ex-smokers had significantly  
53 higher odds than current smokers to agree with this healthcare measure (OR 1.39, 95%CI 1.11-1.73).  
54 Those earning less than 1000€/month had higher odds of supporting this statement than the highest  
55 income group (OR 2.07, 95%CI 1.29-3.31).  
56  
57  
58  
59

#### *Support for measures in the sub-sample of smokers*

When adjusting for socio-demographic characteristics (age, sex, education, household income) in the group of current smokers (**Table 3**), motivation to quit smoking was associated with support for the proposed statement that all health professionals should be trained in offering cessation support: the higher the motivation to quit the greater the odds that a respondent agreed with the statement (continuous variable, OR 1.20, 95%CI 1.04-1.40). No further associations between level of support and smoking characteristics could be found among current smokers.

## **DISCUSSION**

Overall, support in Germany is high for four healthcare policies that would increase the availability and affordability of tobacco cessation treatment: a majority of the adult population support each of four policies. Smoking status was associated with support for two of the four policies, but the odds of agreement were only up to 40% greater among non-smokers than current smokers. Men were less supportive than women but most SES characteristics were not consistently associated with public acceptance.

Acceptance of standard cessation support for patients with chronic physical diseases is higher than of cessation provision for patients with psychological disorders. Compared with the highest income group, people in the lower income groups expressed higher support for standard cessation treatment for the patient group with psychological comorbidities. Prevalence of smoking<sup>25, 26</sup> and of mental health issues<sup>27</sup> is higher in lower SES groups in Germany, similar to other European countries,<sup>28</sup> which could potentially explain these findings. Inequalities persist also for treatment seeking for psychiatric disorders in Germany.<sup>29</sup> A related interesting finding is that the number of people not answering whether they support standard treatment for patients with psychological comorbidities was higher than for other questions. This raises concerns about potential stigmatization of psychiatric illnesses or lack of knowledge about mental health in the general population in Germany. At the same time, this healthcare measure in particular would be of high importance, as patients with mental health issues are more susceptible to tobacco use and could especially profit from standard provision of cessation support.<sup>30</sup> It could be argued that more information about mental health might need to be provided to the public.

We found sex differences in support for statement regarding two statements: support for free cessation treatment among current smokers, and support for standard treatment for patients with

1  
2  
3 physical disorders among the whole sample. Each time men had lower odds of supporting said  
4 healthcare measures. Whether disease concepts, including concepts of addiction,<sup>31</sup> play a role in  
5 these differences needs to be explored further, ideally using both survey data and in-depth  
6 qualitative research.  
7  
8

9  
10 Respondents who indicated a high motivation to quit seem to be more supportive of training  
11 healthcare professionals to advise smokers on how to quit tobacco. In light of the fact that the  
12 majority of quit attempts in Germany occur unaided,<sup>3</sup> this result highlights the need for the  
13 integration of such training into health professional education in Germany.  
14  
15

16  
17 Compared with other European countries, tobacco cessation treatment is not well integrated into  
18 healthcare in Germany, despite knowledge about the burden of disease caused by tobacco use. The  
19 Germany SimSmoke study estimated that over 140,000 lives could be saved between 2020 and 2040  
20 if cessation treatment were provided for free and comprehensively,<sup>32</sup> indicating a potential for better  
21 public health in Germany were such policies implemented.  
22  
23

24  
25 This study has some limitations. We were only able to pose the healthcare measures support  
26 questions in one wave of the DEBRA survey due to resource constraints. It would be interesting to  
27 repeat the assessment in the future to gain insights into temporal trends and sensitivity of public  
28 acceptance in light of actual healthcare policy changes.  
29  
30

31  
32 As the proposed healthcare measures would directly affect healthcare professionals in their training  
33 and work, it would be useful to not only assess public support, but also healthcare professionals'  
34 support towards these measures. As DEBRA is a nationally representative sample, however, findings  
35 give good insights into the overall population. Research with a sample of healthcare professionals  
36 could complement our national study.  
37  
38

39  
40 The measures assessed here are only hypothetical. We are therefore unable to say whether public  
41 support would change in light of actual implementation. In addition, respondents were not asked  
42 about likelihood of such implementation, or who would pay for free cessation treatment. Depending  
43 on the contribution expected from the insured, for instance, answers might be different. Other  
44 studies have found that the public is willing to pay for effective tobacco control<sup>33</sup> however, this  
45 willingness to spend has its limits. At the same time, placing the burden entirely on the insured  
46 instead of dividing it between employers, insurer and the insured is unlikely in Germany's insurance-  
47 based universal healthcare system. Our findings may therefore well reflect the actual likelihood of  
48 support were the measure implemented.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Our findings help fill a knowledge gap on what changes to the tobacco cessation treatment system in  
4 Germany the country's population would agree to. Few studies have assessed public support for  
5 cessation treatment measures rather than tobacco control policies such as taxation or smokefree  
6 legislation. Information on public acceptance for specific tobacco treatment measures is even scarcer  
7 in Germany than for tobacco control. In Germany, DEBRA is one of only a few representative surveys  
8 targeting smoking and tobacco use behaviour,(e.g.,<sup>20, 34</sup>) and is the only one providing both cross-  
9 sectional and longitudinal data on specific tobacco-related questions at 2 month intervals.<sup>20</sup>

14 Making cessation treatment a part of standard care for patients with physical and psychological  
15 disorders is a practice that has already been successful elsewhere,<sup>9</sup> and that would be in line with the  
16 German clinical practice guidelines for the treatment of tobacco addiction.<sup>11, 12</sup> As such, these  
17 proposed healthcare measures are within the realm of the possible. Our findings show that offering  
18 cessation treatment as standard care in Germany would be accepted by the public.

## 22 **Conclusions**

25 Public support for integrating tobacco cessation treatment into the health system is high in Germany,  
26 in both smokers and non- or ex-smokers. Non-smokers were more supportive than current smokers  
27 but it is encouraging that the difference regarding the level of support between these two groups is  
28 small. Socio-demographic characteristics were not consistently associated with public acceptance.  
29 Offering tobacco cessation treatment to patients with physical diseases was generally more accepted  
30 than for patients with mental disorders. Providing cessation treatment offers to all smoking patients  
31 or, as a bare minimum, to those presenting with chronic disorders could be an accepted way forward  
32 in German tobacco control.

## 41 **ABBREVIATIONS**

42 GP = General practitioner

43 CI = Confidence interval

44 DEBRA = German Study on Tobacco Use (In German: "Deutsche Befragung zum Rauchverhalten")

45 FCTC = Framework Convention on Tobacco Control

46 MTSS = Motivation to Stop Scale (In German: MRS = "Motivation zum Rauchstopp Skala")

47 NCSCT = National Centre for Smoking Cessation and Training

48 NRT = Nicotine replacement therapy

49 OR = Odds ratio

50 QOF = Quality Outcome Framework

51 SD = Standard deviation

1  
2  
3 SES = Socioeconomic status

4 STS = Smoking Toolkit Study

5  
6 WHO = World Health Organization

7  
8  
9 **DECLARATIONS**

10 **Acknowledgements**

11 The authors would like to thank: Professor Robert West for support with the DEBRA study design;  
12 Kantar Health (Constanze Cholmakow-Bodechtel and Linda Scharf) for data collection; and Yekaterina  
13 Pashutina for her support with table entries.  
14  
15

16  
17  
18 **Consent to participate**

19 The fieldwork is conducted by the market research institute Kantar Health Munich, Germany. The  
20 interviewers from Kantar Health make sure that all participants give oral informed consent. This  
21 method of consent has been also approved by the ethics committee.  
22  
23  
24

25  
26 **Data sharing statement**

27 All relevant data are within the paper. The data underlying this study are third-party data and are  
28 available to all researchers on reasonable request from the corresponding author.  
29  
30

31  
32 **Patient and Public Involvement statement**

33 Patients were not involved in this study.  
34  
35

36  
37 **Funding**

38 This work was supported by the Ministry for Culture and Science of the German Federal State of  
39 North Rhine-Westphalia ("NRW-Rückkehrprogramm") who had no involvement in the design of the  
40 study, the collection, analysis, and interpretation of data, or in the writing of the manuscript.  
41  
42  
43  
44

45  
46 **Competing interests**

47 SK and MB have no conflict of interest to declare. JB has received unrestricted research funding from  
48 Pfizer, who manufacture smoking cessation medications. LS has received honoraria for talks, an  
49 unrestricted research grant and travel expenses to attend meetings and workshops from Pfizer, and  
50 has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care  
51 companies. DK received an unrestricted grant from Pfizer in 2009 for an investigator-initiated trial on  
52 the effectiveness of practice nurse counselling and varenicline for smoking cessation in primary care  
53  
54  
55  
56  
57

1  
2  
3 (Dutch Trial Register NTR3067). All authors declare no financial links with tobacco companies or e-  
4 cigarette manufacturers or their representatives.  
5  
6

### 7 **Author contributions**

8 SK coordinates the DEBRA study, drafted the manuscript, analysed and interpreted the data. MB co-  
9 wrote the manuscript and interpreted the data. DK conceived the DEBRA study, contributed to the  
10 study design for the policy question analysis, and contributed to the writing of the manuscript. LS  
11 and JB work for the English Smoking Toolkit Study with which DEBRA is closely aligned, and  
12 contributed to the study design as well as to the writing of the manuscript. All named authors  
13 contributed substantially to the manuscript and agreed on its final version.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## REFERENCES

1. WHO. WHO report on the global tobacco epidemic. Warning about the dangers of tobacco 2011. [http://www.who.int/tobacco/global\\_report/2011/en/](http://www.who.int/tobacco/global_report/2011/en/). Accessed 25.06.2018.
2. European Commission. Special Eurobarometer 458. Attitudes of Europeans towards tobacco and electronic cigarettes [accessed 27 November 2017 at [https://data.europa.eu/euodp/en/data/dataset/S2146\\_87\\_1\\_458\\_ENG](https://data.europa.eu/euodp/en/data/dataset/S2146_87_1_458_ENG)]. 2017.
3. Kotz D, Böckmann M, Kastaun S. Nutzung von Tabak und E-Zigaretten sowie Methoden zur Tabakentwöhnung in Deutschland. *Dtsch Arztebl International* 2018;115:235-42.
4. Kuntz B, Zeiher J, Hoebel J, et al. Soziale Ungleichheit, Rauchen und Gesundheit [Social inequalities, Smoking and Health]. *Suchttherapie* 2016;17:115-23.
5. Framework Convention on Tobacco Control (FCTC) Article 14 Guidelines. 2010. [http://www.who.int/fctc/guidelines/adopted/article\\_14/en/](http://www.who.int/fctc/guidelines/adopted/article_14/en/). Accessed 25.06.2018.
6. The Tobacco Control Scale 2016 in Europe. 2016. <http://www.tobaccocontrolscale.org/wp-content/uploads/2017/03/TCS-2016-in-Europe-COMPLETE-LoRes.pdf>. Accessed 27.01.2018.
7. Murray RL, McNeill A. Reducing the social gradient in smoking: initiatives in the United Kingdom. *Drug Alcohol Rev* 2012;31:693-7.
8. Public Health England. 40,000 healthcare professionals trained to help smokers quit. 2017. <https://www.gov.uk/government/news/40000-healthcare-professionals-trained-to-help-smokers-quit>. Accessed 28.01.2018.
9. Szatkowski L, Aveyard P. Provision of smoking cessation support in UK primary care: impact of the 2012 QOF revision. *The British Journal of General Practice* 2016;66:e10-e15.
10. National Health Service (NHS) England. Preventing ill health: Commissioning for Quality and Innovation (CQUIN) supplementary guidance 2017. <https://www.england.nhs.uk/publication/preventing-ill-health-cquin-supplementary-guidance/>. Accessed 07.07.2018.
11. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) S3 Guideline "Screening, Diagnostics, and Treatment of Harmful and Addictive Tobacco Use" [S3-Leitlinie "Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsums"]. AWMF-Register Nr. 076-006. 2015. <http://www.awmf.org/leitlinien/detail/ll/076-006.html>. Accessed 07.05.2018.
12. Andreas S, Batra A, Behr J, et al. Smoking cessation in patients with COPD. [Tabakentwöhnung bei COPD S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.]. *Pneumologie* 2014;68:237-58.
13. Twardella D, Brenner H. Lack of training as a central barrier to the promotion of smoking cessation: a survey among general practitioners in Germany. *Eur J Public Health* 2005;15:140-5.
14. Lorant V, Croux C, Weich S, et al. Depression and socio-economic risk factors: 7-year longitudinal population study. *Br J Psychiatry* 2007;190:293-8.
15. Brown J, West R, Angus C, et al. Comparison of brief interventions in primary care on smoking and excessive alcohol consumption: a population survey in England. *Br J Gen Pract* 2016;66:e1-e9.
16. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction* 2004;99:29-38.
17. Schumann A, John U, Thyrian JR, et al. Attitudes towards smoking policies and tobacco control measures in relation to smoking status and smoking behaviour. *Eur J Publ Health* 2006;16:513-19.
18. Keller S, Weimer-Hablitzel B, Kaluza G, et al. Einstellungen zur Raucherpolitik in Abhängigkeit vom aktuellen Raucherstatus. [Attitudes towards smoking policy and smoking status]. *Z Med Psychol* 2002;11:177-84.

19. Schaller K, Braun S, Pötschke-Langer M. Erfolgsgeschichte Nichtraucherschutz in Deutschland: Steigende Unterstützung in der Bevölkerung für gesetzliche Maßnahmen [Success story protection from second-hand smoke exposure in Germany: Increased public support for legislative measures]. *Gesundheitsmonitor News* 2014;1-9.
20. Kastaun S, Brown J, Brose LS, et al. Study protocol of the German Study on Tobacco Use (DEBRA): a national household survey of smoking behaviour and cessation. *BMC Public Health* 2017;17:378.
21. Boeckmann M, Kotz D, Shahab L, et al. German Public Support for Tobacco Control Policy Measures: Results from the German Study on Tobacco Use (DEBRA), a Representative National Survey. *Int J Environ Res Public Health* 2018;15.
22. Kotz D, Brown J, West R. Predictive validity of the Motivation To Stop Scale (MTSS): A single-item measure of motivation to stop smoking. *Drug & Alcohol Depend*;128:15-19.
23. Fidler JA, Shahab L, West O, et al. 'The smoking toolkit study': a national study of smoking and smoking cessation in England. *BMC Public Health* 2011;11:479.
24. Bowling A. Mode of questionnaire administration can have serious effects on data quality. *J Public Health* 2005;27:281-91.
25. Hoebel J, Kuntz B, Kroll LE, et al. Trends in Absolute and Relative Educational Inequalities in Adult Smoking Since the Early 2000s: The Case of Germany. *Nicotine Tob Res* 2018;20:295-302.
26. Lampert T, von der Lippe E, Müters S. Verbreitung des Rauchens in der Erwachsenenbevölkerung in Deutschland. *Bundesgesundhbl Gesundheitsforsch Gesundheitsschutz* 2013;56:802-08.
27. Pinto-Meza A, Moneta MV, Alonso J, et al. Social inequalities in mental health: results from the EU contribution to the World Mental Health Surveys Initiative. *Soc Psychiatry Psychiatr Epidemiol* 2013;48:173-81.
28. Mackenbach JP, Stirbu I, Roskam AJ, et al. Socioeconomic inequalities in health in 22 European countries. *N Engl J Med* 2008;358:2468-81.
29. Epping J, Muschik D, Geyer S. Social inequalities in the utilization of outpatient psychotherapy: analyses of registry data from German statutory health insurance. *Int J Equity Health* 2017;16:147.
30. Mohd Hairi F, Mackenbach JP, Andersen-Ranberg K, et al. Does socio-economic status predict grip strength in older Europeans? Results from the SHARE study in non-institutionalised men and women aged 50+. *J Epidemiol Community Health* 2010;64:829-37.
31. Racine E, Sattler S, Escande A. Free Will and the Brain Disease Model of Addiction: The Not So Seductive Allure of Neuroscience and Its Modest Impact on the Attribution of Free Will to People with an Addiction. *Front Psychol* 2017;8:1850.
32. Levy DT, Blackman K, Currie LM, et al. Germany SimSmoke: the effect of tobacco control policies on future smoking prevalence and smoking-attributable deaths in Germany. *Nicotine Tob Res* 2013;15:465-73.
33. Sanders AE, Slade GD, Ranney LM, et al. Valuation of tobacco control policies by the public in North Carolina: comparing perceived benefit with projected cost of implementation. *N C Med J* 2012;73:439-47.
34. Piontek D, Kraus L, Matos EGd, et al. Der Epidemiologische Suchtsurvey 2015. *SUCHT* 2016;62:259-69.

**Table 1** Baseline characteristics of the total sample, and by smoking status (unweighted data)<sup>a</sup>

	Total sample (N = 2,062; 100%)	Current smoker (N = 586; 28.4%)	Ex-smoker (N = 369; 17.9%)	Never smoker (N = 1,107; 53.7%)
Age, years (mean ± SD)	51.8 ± 19.8	47.1 ± 17.2	58.4 ± 17.5	52.1 ± 21.1
Sex				
Female	1,070 (51.9%)	271 (46.2%)	143 (38.8%)	656 (59.3%)
Male	992 (48.1%)	315 (53.8%)	226 (61.2%)	451 (40.7%)
Education <sup>b</sup>				
High school equiv.	479 (23.2%)	110 (19.2%)	85 (23.2%)	284 (27.4%)
Adv. tech. college equiv.	133 (6.5%)	28 (4.9%)	30 (8.2%)	75 (7.2%)
Secondary school equiv.	686 (33.3%)	230 (40.1%)	116 (31.7%)	340 (32.8%)
Junior high school equiv.	646 (31.3%)	193 (33.6%)	130 (35.5%)	323 (31.1%)
No qualification	33 (1.6%)	13 (2.3%)	5 (1.4%)	15 (1.45%)
Household income				
>€5000 /per month	134 (6.5%)	26 (4.4%)	27 (7.3%)	81 (7.3%)
€4000-5000/per month	128 (6.2%)	31 (5.3%)	24 (6.5%)	73 (6.6%)
€3000-4000/per month	369 (17.9%)	96 (16.4%)	67 (18.2%)	206 (18.6%)
€2000-3000/per month	557 (27.0%)	164 (28.0%)	106 (28.7%)	287 (25.9%)
€1000-2000/per month	638 (30.9%)	173 (29.5%)	117 (31.7%)	348 (31.4%)
< €1,000/per month	236 (11.4%)	96 (16.4%)	28 (7.6%)	112 (10.1%)

<sup>a</sup>Baseline characteristics of the sample have also been published elsewhere<sup>21</sup> under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited: CC BY 4.0. Data are presented as number (% within row), unless otherwise stated. <sup>b</sup>German equivalents to education levels listed in table from highest to lowest: high school equivalent = "Allgemeine Hochschulreife," advanced technical college equivalent = "Fachhochschulreife," secondary school equivalent = "Realschulabschluss," junior high school equivalent = "Hauptschulabschluss."

**Table 2** Smoking characteristics of current smokers (unweighted data)

	Current smokers only (N = 586)
Cigarettes smoked per day (mean $\pm$ SD)	15.3 $\pm$ 9.0
Made at least one quit attempt last year	140 (23.9%)
Motivation to stop smoking <sup>20</sup>	
Don't want to stop smoking	268 (45.7%)
Should stop but don't really want to	139 (23.7%)
Want to stop but haven't thought about when	52 (8.9%)
Want to stop but haven't decided when	51 (8.7%)
Really want to stop and hope to soon	43 (7.3%)
Really want to stop and intend to in the next 3 months	7 (1.2%)
Really want to stop and intend to in the next month	6 (1.0%)

Data are presented as number (%), unless otherwise stated.

**Table 3** Multivariable associations with support for the proposed healthcare measures in the total sample (N = 2,062), and in current smokers (N = 586)

	Every smoker gets cessation treatment for free	Training all healthcare professionals to advise smokers	Cessation support as standard care for smokers (physical diseases)	Cessation support as standard care for smokers (mental illness)
Smoking status				
Current smoker (ref.)	1	1	1	1
Ex-smoker	0.88 (0.67-1.16)	1.43 (1.07-1.92)*	1.37 (1.00-1.88)	1.19 (0.89-1.58)
Never smoker	0.88 (0.71-1.09)	1.43 (1.14-1.79)**	1.05 (0.83-1.33)	1.39 (1.11-1.73)**
Age, 10-year units <sup>a</sup>	1.01 (0.96-1.06)	1.05 (1.00-1.11)	1.06 (1.00-1.13)*	1.05 (1.00-1.11)
Sex				
Female (ref.)	1	1	1	1
Male	0.80 (0.66-0.97)*	0.83 (0.68-1.01)	0.74 (0.60-0.91)**	0.91 (0.75-1.10)
Education <sup>b</sup>				
High school equiv. (ref.)	1	1	1	1
Adv. tech. college equiv.	1.50 (1.00-2.24)*	1.16 (0.76-1.77)	1.21 (0.77-1.92)	1.41 (0.93-2.13)
Secondary school equiv.	1.34 (1.05-1.72)*	1.15 (0.88-1.49)	1.02 (0.77-1.34)	1.06 (0.82-1.37)
Junior high school equiv.	1.36 (1.03-1.79)*	0.99 (0.75-1.32)	0.93 (0.69-1.26)	1.23 (0.93-1.63)
No qualification	1.07 (0.49-2.34)	1.68 (0.69-4.11)	1.19 (0.49-2.91)	0.86 (0.39-1.91)
Household income				
€>5000/per month (ref.)	1	1	1	1
€4000-5000/per month	0.99 (0.60-1.64)	0.70 (0.42-1.19)	1.23 (0.69-2.19)	1.32 (0.79-2.21)
€3000-4000/per month	1.04 (0.69-1.58)	0.88 (0.56-1.36)	1.03 (0.65-1.165)	1.59 (1.04-2.43)*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

€2000-3000/per month	0.92 (0.62-1.38)	0.87 (0.57-1.33)	0.84 (0.54-1.32)	1.39 (0.92-2.10)
€1000-2000/per month	1.02 (0.68-1.53)	0.91 (0.59-1.40)	1.05 (0.67-1.64)	1.56 (1.03-2.37)*
< €1,000/per month	1.53 (0.97-2.43)	1.10 (0.67-1.78)	1.22 (0.73-2.04)	2.07 (1.29-3.31)**

**Current smokers only (N = 586)**

Cigarettes smoked/day, number <sup>c</sup>	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)
Quit attempt last year (yes/no)				
Yes, attempt to quit (ref.)	1	1	1	1
No, attempt to quit	0.80 (0.51-1.26)	0.70 (0.44-1.11)	0.91 (0.56-1.48)	0.84 (0.54-1.32)
Motivation to stop smoking (MRS) <sup>3</sup>	1.00 (0.87-1.14)	1.20 (1.04-1.40)*	1.14 (0.98-1.33)	0.95 (0.83-1.08)

Data are presented as adjusted OR (95% confidence interval around OR). Ref. = reference group. \*p<0.05; \*\*p<0.01. <sup>a</sup>continuous variable: age units are based on DEBRA study participation eligibility (14 years and older): 14-23; 24-33; 34-43; 44-53; 54-63; 64-73; 74-83; 84-93; 94-103, <sup>b</sup>German equivalents to education levels listed in table from highest to lowest: high school equivalent = "Allgemeine Hochschulreife," advanced technical college equivalent = "Fachhochschulreife," secondary school equivalent = "Realschulabschluss," junior high school equivalent = "Hauptschulabschluss", <sup>c</sup>continuous variable (MRS: increasing from 1 "don't want to top" to 7 "really want to stop, intend to in the next month").

1  
2  
3 **Figure Legends**  
4

5 **Figure 1** Proportion (with 95% confidence interval) of public support for healthcare policies (N=2,062  
6 respondents, weighted data).  
7  
8  
9

10  
11 **Figure 2** Proportion (with 95% confidence interval) of support for healthcare policies in the  
12 subsample of current smokers (N=586 respondents, weighted data).  
13  
14  
15

16  
17  
18 **Additional files**

19 Additional file 1: Supplementary Table1\_DEBRA\_BMJopen.pdf (Content: Results of multivariable  
20 associations with support for the proposed healthcare measures in never- and ex-smokers (N =  
21 1,476)).  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 Proportion (with 95% confidence interval) of public support for healthcare policies (N=2,062 respondents, weighted data).

104x66mm (600 x 600 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2 Proportion (with 95% confidence interval) of support for healthcare policies in the subsample of current smokers (N=586 respondents, weighted data).

104x58mm (600 x 600 DPI)

**Supplementary Table 1** Multivariable associations with support for the proposed healthcare measures in never- and ex-smokers (N = 1,476)

	Every smoker gets cessation treatment for free	Training all healthcare professionals to advise smokers	Cessation support as standard care for smokers (physical diseases)	Cessation support as standard care for smokers (mental diseases)
Age, 10-year units <sup>a</sup>	0.99 (0.93-1.05)	1.05 (0.99-1.12)	1.08 (1.01-1.16)*	1.04 (0.98-1.11)
Sex				
Female (ref.)	1	1	1	1
Male	0.90 (0.72-1.12)	0.90 (0.71-1.14)	0.82 (0.64-1.05)	0.97 (0.78-1.23)
Education <sup>†</sup>				
High school equiv. (ref.)	1	1	1	1
Advanced technical college equiv.	1.50 (0.95-2.36)	1.14 (0.70-1.83)	1.08 (0.65-1.82)	1.44 (0.89-2.32)
Secondary school equiv.	1.36 (1.01-1.83)*	1.44 (1.04-1.94)	1.06 (0.76-1.48)	1.07 (0.79-1.46)
Junior high school equiv.	1.42 (1.03-1.97)*	1.05 (0.75-1.49)	0.86 (0.60-1.24)	1.15 (0.82-1.61)
No qualification	0.54 (0.19-1.58)	1.03 (0.34-3.08)	0.68 (0.23-2.03)	0.49 (0.17-1.38)
Household income				
€>5000/per month (ref.)	1	1	1	1
€4000-5000/per month	1.08 (0.62-1.91)	0.63 (0.34-1.16)	1.46 (0.75-2.85)	1.74 (0.95-3.16)
€3000-4000/per month	1.13 (0.70-1.80)	0.79 (0.47-1.31)	1.14 (0.67-1.93)	1.67 (1.03-2.72)*
€2000-3000/per month	1.03 (0.66-1.62)	0.76 (0.46-1.24)	0.88 (0.53-1.46)	1.42 (0.89-2.28)
€1000-2000/per month	1.00 (0.64-1.58)	0.82 (0.50-1.36)	1.09 (0.65-1.82)	1.70 (1.06-2.72)*
< €1,000/per month	1.62 (0.93-2.80)	1.16 (0.64-2.13)	1.65 (0.87-3.12)	2.09 (1.19-3.69)*

Data are presented as adjusted OR (95% confidence interval around OR). Ref. = reference group. \*p<0.05; \*\*p<0.01; <sup>a</sup>continuous variable, <sup>†</sup>German equivalents to education levels listed in table from highest to lowest: high school equivalent = "Allgemeine Hochschulreife," advanced technical college equivalent = "Fachhochschulreife," secondary school equivalent = "Realschulabschluss," junior high school equivalent = "Hauptschulabschluss." Age units are based on DEBRA study participation eligibility (14 and older): 14-23; 24-33; 34-43; 44-53; 54-63; 64-73; 74-83; 84-93; 94-103.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4ff.
Objectives	3	State specific objectives, including any prespecified hypotheses <sup>1</sup>	Exploratory design
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5/6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6/7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6/7
Bias	9	Describe any efforts to address potential sources of bias	6-8
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	6, 8
		(e) Describe any sensitivity analyses	-
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6,8,9
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9, Table 1 (17)
		(b) Indicate number of participants with missing data for each variable of interest	8
Outcome data	15*	Report numbers of outcome events or summary measures	9, Figure 1 and 2
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9,10, Table 3 (19)
		(b) Report category boundaries when continuous variables were categorized	Table 3 (19/20)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8,9,10
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10,11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Public attitudes towards healthcare policies promoting tobacco cessation in Germany: results from the representative German Study on Tobacco Use (the DEBRA study)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026245.R1
Article Type:	Research
Date Submitted by the Author:	23-Apr-2019
Complete List of Authors:	Kastaun, Sabrina; Heinrich-Heine-University, Düsseldorf, Institute of General Practice, Addiction Research and Clinical Epidemiology Unit Kotz, Daniel; Heinrich-Heine-University Duesseldorf, Institute of General Practice, Addiction Research and Clinical Epidemiology Unit; University College London, Department of Behavioural Science and Health Brown, Jamie; University College London, Department of Behavioural Science and Health Shahab, Lion; University College London, Department of Behavioural Science and Health Boeckmann, Melanie; Medical Faculty of the Heinrich-Heine-University, Institute of General Practice; Bielefeld University, Department Environment and Health, School of Public Health
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Smoking and tobacco
Keywords:	PUBLIC HEALTH, EPIDEMIOLOGY, PRIMARY CARE

SCHOLARONE™  
Manuscripts

1  
2 **Public attitudes towards healthcare policies promoting tobacco cessation in Germany:**  
3  
4 **results from the representative German Study on Tobacco Use (the DEBRA study)**  
5

6 Sabrina Kastaun<sup>1\*</sup>, Daniel Kotz<sup>1,2</sup>, Jamie Brown<sup>2</sup>, Lion Shahab<sup>2</sup>, Melanie Boeckmann<sup>1,3</sup>  
7  
8  
9

10  
11 <sup>1</sup>Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of  
12 the Heinrich-Heine-University, Düsseldorf, Germany  
13  
14

15 <sup>2</sup>Department of Behavioural Science and Health, University College London, London, UK  
16  
17

18 <sup>3</sup>Department Environment and Health, School of Public Health, Bielefeld University, Bielefeld,  
19 Germany  
20  
21

22  
23  
24  
25 **\*Correspondence**

26 Dr. Sabrina Kastaun, Institute of General Practice, Addiction Research and Clinical Epidemiology Unit,  
27 Medical Faculty of the Heinrich-Heine-University Düsseldorf, Werdener Str. 4, 40227 Düsseldorf,  
28 Germany, Tel: 0049-211-81-19527, Mail: [Sabrina.Kastaun@med.uni-duesseldorf.de](mailto:Sabrina.Kastaun@med.uni-duesseldorf.de), Website:  
29 [www.debra-study.info](http://www.debra-study.info).  
30  
31  
32  
33

34  
35 **Email co-authors**

36 Daniel Kotz: [daniel.kotz@med.uni-duesseldorf.de](mailto:daniel.kotz@med.uni-duesseldorf.de)

37 Jamie Brown: [jamielbrown10@gmail.com](mailto:jamielbrown10@gmail.com)

38 Lion Shahab: [lion.shahab@ucl.ac.uk](mailto:lion.shahab@ucl.ac.uk)

39 Melanie Boeckmann: boeckmannmelanie@gmail.com  
40  
41  
42  
43  
44  
45

46 **Manuscript word count:**

47  
48 Main text: 3,264 (excluded: title page, abstract, references, tables, declarations)

49  
50 Abstract: 253 words

51  
52 Tables: 3

53  
54 Figures: 2

55  
56 Supplementary files: 1  
57  
58  
59  
60

## 1 ABSTRACT

### 2 Objective

3 The aim of this study was to assess public acceptance of four possible healthcare policies supporting  
4 tobacco dependence treatment in line with Framework Convention for Tobacco Control (FCTC)  
5 Article 14 recommendations in Germany.

### 6 Design

7 Cross-sectional household survey.

### 8 Setting

9 Data were drawn from the German population and collected through computer-assisted, face-to-  
10 face interviews.

### 11 Participants

12 Representative random sample of 2,087 people ( $\geq 14$  years) of the German population.

### 13 Outcome measures

14 Public acceptance was measured regarding 1) treatment cost reimbursement, 2) standard training on  
15 offering cessation treatment for health professionals, and making cessation treatment a standard  
16 part of care for smokers with 3) physical or 4) mental disorders. Associations with smoking status and  
17 socio-economic (SES) characteristics were assessed.

### 18 Results

19 Support for all policies was high (50%-68%), even among smokers (48%-66%). Ex- or never-smokers  
20 were more likely to support standard training on cessation for health professionals than current  
21 smokers (OR 1.43, 95%CI 1.07–1.92; OR 1.43; 95%CI 1.14–1.79, respectively). Ex-smokers were also  
22 more likely than current smokers to support cessation treatment for smokers with mental disorders  
23 (OR 1.39, 95%CI 1.11–1.73). Men were less likely than women to support cessation treatment for  
24 smokers with physical diseases (OR 0.74, 95%CI 0.60–0.91) and free provision of treatment (OR 0.80,  
25 95%CI 0.66–0.97). Offering cessation treatment to smokers with physical disorders was generally  
26 more accepted than to those with mental health issues.

### 27 Conclusions

28 The majority of the German population supports healthcare policies to improve the availability and  
29 affordability of tobacco dependence treatment. Non-smokers were more supportive than current

1 smokers of two of the four policies, but odds of support were only about 40% greater. SES  
2 characteristics were not consistently associated with public acceptance.

### 3 **Trial registration number**

4 [4 DRKS00011322](https://www.drks.de/DRKS00011322)

### 6 **Strengths and limitations of this study**

- 7 • This is the first study helping to fill a knowledge gap on what changes to the tobacco  
8 cessation treatment system in Germany the country's population would agree to.
- 9 • Data was obtained from a sample which is representative for the German population.
- 10 • Analysis takes into account sociodemographic and socioeconomic factors as well as smoking  
11 status of the respondents.
- 12 • Since assessed policies are only hypothetical, we are unable to say whether public support  
13 would change in light of actual implementation.
- 14 • It would also be important to gain insight into the healthcare professionals' perspective  
15 regarding the support towards healthcare policies promoting tobacco cessation in Germany

### 18 **Key words**

19 Healthcare policy, Public opinion, Smoking cessation, Household Survey



## 1 INTRODUCTION

2 Treating tobacco use is a major public health issue: smoking remains a leading cause of death, killing  
3 approximately 6 million people worldwide each year.<sup>1</sup> Compared with other Western European  
4 countries, e.g. the Netherlands (19%), England (17%), or Sweden (7%),<sup>2</sup> the prevalence of tobacco  
5 smoking in Germany remains high (28%).<sup>3</sup> Moreover, smoking is unequally distributed across  
6 different groups within the population, with higher rates of smoking in more disadvantaged  
7 socioeconomic groups<sup>3, 4</sup> and in people with poor mental health.<sup>5</sup> Hence, interventions to reduce  
8 tobacco consumption should also aim to decrease tobacco-related health inequalities, and smoking  
9 cessation treatment as part of health services should be equally accessible to all social groups.

10 Article 14 of the World Health Organization (WHO) Framework Convention on Tobacco Control  
11 (FCTC) [1] states that ratifying countries should take effective measures to promote cessation of  
12 tobacco use and provide adequate treatment for tobacco dependence.<sup>6</sup> To assist countries in  
13 fulfilling these obligations, guidelines for the implementation of Article 14 of the WHO FCTC have  
14 been developed,<sup>6</sup> proposing the following healthcare policies to reduce national smoking prevalence:  
15 integrating brief advice to quit smoking into all health-care systems; ensuring that all health care  
16 workers are trained to provide brief smoking cessation support to their smoking patients; using  
17 existing health infrastructures for access to tobacco cessation (including primary care); and making  
18 evidence-based smoking cessation medication available to all smokers wanting to quit, either freely  
19 or at least at an affordable cost.

20 Whereas other European countries that ratified the FCTC made substantial progress to put these  
21 healthcare measures into practice, the level of implementation in Germany is comparably poor.<sup>7</sup>  
22 Evidence-based treatments are still not, or only partly, reimbursed and stop-smoking services rarely  
23 exist. According to national clinical guidelines, evidence-based cessation methods and brief advice to  
24 quit tobacco should be routinely offered to smoking patients in medical and psychosocial healthcare  
25 settings.<sup>8, 9</sup> However, GPs lack training in smoking cessation promotion as training is not a standard  
26 part of medical education, and to date no specific reimbursement is provided to GPs for offering brief  
27 smoking cessation counselling.<sup>10</sup>

28 As a consequence, less than 20% of smokers in Germany visiting their GP in the past year report  
29 receiving brief smoking cessation counselling,<sup>11</sup> which contrasts with England where half of all  
30 smokers report having received counselling.<sup>12</sup> The majority (> 80%) of smokers in Germany still try to  
31 quit unaided or with the use of non-evidence-based treatments,<sup>3</sup> and thus limit their chances of  
32 success.<sup>13</sup> Hence, there is an urgent need to improve implementation of Article 14 FCTC in German  
33 healthcare.

1  
2 1 Implementation of healthcare policies tackling smoking prevalence at population level can only be  
3  
4 2 successful if it is broadly accepted by the public and used by those affected. However, little is  
5  
6 3 currently known about public support for healthcare policies to reduce tobacco-related health  
7  
8 4 effects in Germany. The few existing studies focus exclusively on public attitudes towards tobacco  
9  
10 5 control measures such as increasing taxes, improving public education, and environmental  
11  
12 6 restrictions.<sup>14-16</sup>

13 7 Appropriate data are needed to improve the understanding of structural possibilities for the  
14  
15 8 implementation of policies in German healthcare. Implementation usually requires political will,  
16  
17 9 which often relies on understanding the level of public support. The German Study on Tobacco Use  
18  
19 10 (DEBRA), an ongoing national representative survey, provides such data.

## 11 **Objective**

12 The aim of this study was to assess public support for possible legislative changes on healthcare  
13  
14 13 policies that, according to Article 14 WHO FCTC, should have long been implemented in German  
15  
16 14 healthcare.

## 16 **METHODS**

### 17 **Design, setting, and participants**

18 Data on public support for the implementation of potential healthcare policies were collected as part  
19  
20 18 of the nationally representative DEBRA study ("DEutsche Befragung zum RAuchverhalten",  
21  
22 19 [www.debra-study.info](http://www.debra-study.info)). DEBRA started in June 2016 and consists of cross-sectional, computer-  
23  
24 20 assisted household interviews in people aged 14 years and older, carried out by a market research  
25  
26 21 institute as part of a larger omnibus survey. Over a period of at least 3 years, a new representative  
27  
28 22 sample of approximately 2,000 respondents of the German population will complete the survey  
29  
30 23 every two months. Beyond smoking status, smoking and quitting behaviour, use of cessation  
31  
32 24 methods and of electronic cigarettes, respondents report on socio-demographic characteristics.  
33  
34 25 Methodological details, including details of the sampling approach, as well as the complete DEBRA  
35  
36 26 questionnaire have been published in the study protocol.<sup>17</sup> The study was conducted in accordance  
37  
38 27 with the Declaration of Helsinki, and the protocol of this study has been peer-reviewed and approved  
39  
40 28 by the ethics committee of the Heinrich-Heine-University Duesseldorf, Germany (ID 5386/R).

41  
42 29 Questions on public support for specific policies were asked during wave 2 of the study in  
43  
44 30 August/September 2016, in a total sample of 2,087 respondents. For this wave, questions on public  
45  
46 31 acceptance towards a) tobacco control strategies and b) healthcare policy were included. Findings  
47  
48 32

1 on legislative tobacco control strategies such as a total ban of tobacco products or raising the legal  
2 age for tobacco consumption have been published elsewhere.<sup>18</sup> This article discusses findings of the  
3 questions on public attitudes towards healthcare policies suggested in Article 14 of the WHO FCTC.

## 5 **Measures**

### 6 *Socio-demographic and smoking characteristics*

7 Socio-demographic data on age, sex, education and net household income from all respondents are  
8 routinely collected in the omnibus survey by the market research institute. In the current analysis,  
9 level of education of every respondent was categorised from highest to lowest as 5 = high school  
10 equivalent ("Allgemeine Hochschulreife"), 4 = advanced technical college equivalent  
11 ("Fachhochschulreife"), 3 = secondary school equivalent ("Realschulabschluss"), 2 = junior high  
12 school equivalent ("Hauptschulabschluss"), and as 1 = no qualification. Respondents provided a point  
13 estimate of their net household income, which was categorised into 6 = more than 5000€/month, 5 =  
14 4000- less than 5000€/month, 3 = 2000 - less than 3000€/month, 4 = 3000 - less than 4000€/month,  
15 2 = 1000- less than 2000€/month, and 1 = less than 1000€/month. Respondents were categorised as  
16 current tobacco smokers (cigarettes or other combustible tobacco products), as ex-smokers if they  
17 had stopped during the past year or more than a year ago, or as never smokers if they had never  
18 smoked for a year or longer.

19 Current smokers of tobacco products were asked further details on their smoking behaviour: number  
20 of cigarettes smoked per day (answers per week or month were converted for analyses), about their  
21 current motivation to quit smoking using the translated and culturally adapted German version of  
22 the Motivation to Stop Smoking Scale,<sup>19</sup> and whether or not they made at least one quit attempt  
23 during the past year.

### 25 *Measuring public support for healthcare policies*

26 Public support was assessed with four suggestions on potential healthcare policies related to tobacco  
27 cessation. These suggestions have been adapted from the Smoking Toolkit Study (STS),<sup>20</sup> a  
28 methodologically comparable household survey, allowing comparisons with data from England at a  
29 later stage.

30 Participants were asked whether they would (a) "strongly support", (b) "tend to support", (c) "have  
31 no opinion either way", (d) "tend to oppose", (e) "strongly oppose", or (f) "don't want to answer" the

1  
2 1 four statements listed below. Answers are classified into “agree” (a and b), “disagree” (d and e),  
3 2 “undecided” (c) and “no answer” (f), and further dichotomised for the regression analyses into  
4 3 “agree” (a and b) and “don’t agree” (c, d and e), with those responding ‘f’ excluded.

5  
6  
7  
8 4 1. “Every smoker who wants should get support that is clinically proven to help stop smoking, and  
9 5 costs for these treatments (pharmacological or behavioural smoking cessation therapy) should be  
10 6 reimbursed”.

11  
12  
13 7 2. “Making sure that all healthcare professionals directly involved in the treatment or care of  
14 8 patients are trained to advise smokers on how to stop smoking”.

15  
16  
17 9 3. “Making stop-smoking support a standard part of care for smokers with long-term physical health  
18 10 problems (such as cardiovascular or respiratory diseases)”.

19  
20  
21 11 4. “Making stop-smoking support a standard part of care for smokers with mental health problems  
22 12 (such as depression or schizophrenia)”.

23  
24  
25  
26 13 Statements were asked in a random order to avoid primacy and recency effects.<sup>21</sup>

## 27 28 29 30 31 15 **Data analysis**

32  
33 16 Descriptive analyses using unweighted data were carried out to characterise the total sample as well  
34 17 as the subsamples according to smoking status of respondents. For categorical variables, proportions  
35 18 were computed and for continuous variables, data were presented in terms of means and standard  
36 19 deviations (SD).

37  
38  
39  
40  
41 20 To provide prevalence data on public support for potential healthcare policies, the sample was  
42 21 weighted to be representative of the German population. Details on weighting procedures have been  
43 22 published in the study protocol.<sup>17</sup>

44  
45  
46  
47 23 Associations between support of suggested healthcare policies and sample characteristics were  
48 24 assessed with exploratory multivariable logistic regression analyses using unweighted data  
49 25 (dichotomous dependent variable “agree on a potential healthcare policy” (agree vs. disagree)). A  
50 26 second multivariable model was run with the subsample of current smokers, assessing associations  
51 27 between support of suggested healthcare policies and smoking characteristics. Sample  
52 28 characteristics included in both models were sex, age, net household income, education, and  
53 29 smoking status. For the subgroup analysis in current smokers, the following smoking characteristics  
54 30 were also included: number of cigarettes smoked per day, current motivation to stop smoking,<sup>18</sup> and  
55 31 attempts to quit smoking (any vs. none) during the past year. To assess whether the sub-sample of

1 smokers differed from the sub-sample of non- and ex-smokers, we ran a third regression model for  
2 the latter group separately (Supplementary Table 1).

3 Out of the total sample, 25 respondents (1.1% of the total sample) refused to disclose their smoking  
4 status and were thus excluded from all analyses. Respondents who refused to answer questions on  
5 either their educational level, their attempts to quit smoking, or on questions regarding their support  
6 for potential healthcare policies were only excluded from the multivariate logistic regression analyses  
7 (statement 1 = 177 missing (8.6%), statement 2 = 187 missing (9.1%), statement 3 = 179 missing  
8 (8.7%), and statement 4 = 245 missing (11.9%)).

## 10 RESULTS

### 11 Sample characteristics

12 Unweighted baseline characteristics of the analysed sample of 2,062 respondents with full data on  
13 their smoking status are presented in **Table 1**. The sample had a mean age of 51.8 years (standard  
14 deviation [SD] =  $\pm$  20 years), and 1,070 (51.9%) of the respondents were female. In total, 1,107  
15 (53.7%, 95% confidence interval [CI] = 51%-55%) respondents were never smokers, 369 (17.9%,  
16 95%CI = 16%-19%) were ex-smokers, and 586 (28.4%, 95%CI = 26%-30%; unweighted) were current  
17 smokers. **Table 2** presents data on smoking characteristics for this subsample of current smokers.

### 19 Public support for healthcare policies

20 **Figure 1** presents rates of support for suggested healthcare policies weighted to be representative  
21 for the German population. All four policies receive support from the majority of the population. Of  
22 the total sample, 52% (95%CI = 50%-55%) agreed to providing cessation support to every smoker for  
23 free, 62% (95%CI = 60%-64%) would support standard training on cessation for health professionals,  
24 68% (95%CI = 66%-70%) would support cessation as standard care for patients with chronic physical  
25 diseases, and half of the sample (50%, 95%CI = 47%-51%) supports cessation for patients with mental  
26 disorders.

27 Among the subsample of current smokers (**Figure 2**), the majority also agreed with all four healthcare  
28 policies, with standard cessation provision for patients with physical comorbidities again ranking  
29 highest at 66% (95%CI = 62%-70%). Slightly fewer smokers (54%, 95%CI = 50%-58%) than in the total  
30 sample would support standard training for all health professionals.

### 31 Factors associated with public support

**Table 3** presents the results of the multivariable logistic regression for the suggested healthcare policies for the total unweighted sample, and for the subgroup of current smokers (for the sake of completeness we ran the regression model again for the group of non- and ex-smokers, please see Supplementary Table 1). Overall, socio-demographic and smoking characteristics are not consistently associated with support for proposed healthcare policies, with the exception of sex and smoking status.

Men had lower odds of agreeing with **1) free provision of cessation treatment** (OR 0.80, 95%CI 0.66 – 0.97) than women. Household income showed no significant associations with support for the policy, while those with education levels of junior high school equivalent to advanced technical college equivalent had higher odds of supporting free provision (OR 1.36, 95%CI 1.03-1.79; OR 1.34, 95%CI 1.05-1.72, OR 1.50, 95%CI 1.00-2.24).

Standard **2) training of health professionals** in cessation had higher odds of being supported by ex- or never-smokers (OR 1.43, 95%CI 1.07-1.92 and OR 1.43, 95%CI 1.14-1.79, respectively) than current smokers.

Men were less likely than women to support **3) cessation as standard care for patients with physical diseases** (OR 0.74, 95%CI 0.60-0.91).

Regarding **4) cessation as standard care for patients with mental illness**, ex-smokers had significantly higher odds than current smokers to agree with this healthcare policy (OR 1.39, 95%CI 1.11-1.73). Those earning less than 1000€/month had higher odds of supporting this statement than the highest income group (OR 2.07, 95%CI 1.29-3.31).

#### *Support for policies in the sub-sample of smokers*

When adjusting for socio-demographic characteristics (age, sex, education, household income) in the group of current smokers (**Table 3**), motivation to quit smoking was associated with support for the proposed statement that all health professionals should be trained in offering cessation support: the higher the motivation to quit the greater the odds that a respondent agreed with the statement (continuous variable, OR 1.20, 95%CI 1.04-1.40). No further associations between level of support and smoking characteristics could be found among current smokers.

## **DISCUSSION**

Overall, support in Germany is high for four healthcare policies that would increase the availability and affordability of tobacco cessation treatment: a majority of the adult population support each of

1  
2 1 four policies. Smoking status was associated with support for two of the four policies, but the odds of  
3 2 agreement were only up to 40% greater among non-smokers than current smokers. These findings  
4 3 are in line with results from 89 surveys on smokefree policy in the US and Canada;<sup>22</sup> however, a study  
5 4 from China found equal support for policies among smokers and non-smokers.<sup>23</sup> Men were less  
6 5 supportive than women, which was also observed in the review from the US and Canada,<sup>22</sup> but most  
7 6 SES characteristics were not consistently associated with public acceptance.

7 7 Acceptance of standard cessation support for patients with chronic physical diseases is higher than of  
8 8 cessation provision for patients with mental health issues. Compared with the highest income group,  
9 9 people in the lower income groups expressed higher support for standard cessation treatment for  
10 10 the patient group with mental health comorbidities. Prevalence of smoking<sup>24, 25</sup> and of mental health  
11 11 issues<sup>26</sup> is higher in lower SES groups in Germany, similar to other European countries,<sup>27</sup> which could  
12 12 potentially explain these findings. Inequalities persist also for treatment seeking for psychiatric  
13 13 disorders in Germany.<sup>28</sup> Another possible explanation are misconceptions relating to smoking and  
14 14 mental health. A recent systematic review found that even among mental health professionals,  
15 15 smoking is often perceived as a tool to manage stress in patients, and some mental health  
16 16 professionals believe that quitting smoking may be too much for their patients to take on while in  
17 17 treatment.<sup>29</sup>

18 18 A related interesting finding is that the number of people not answering whether they support  
19 19 standard treatment for patients with mental health comorbidities was higher than for other  
20 20 questions. This raises concerns about potential stigmatization of psychiatric illnesses or lack of  
21 21 knowledge about mental health in the general population in Germany. At the same time, this  
22 22 healthcare policy in particular would be of high importance, as patients with mental health issues are  
23 23 more susceptible to tobacco use<sup>5</sup> and could especially profit from standard provision of cessation  
24 24 support.<sup>30</sup> It could be argued that more information about mental health might need to be provided  
25 25 to the public. Integrating information on study participants' mental health conditions and treatment  
26 26 into future or ongoing population surveys could further support research on cessation for these  
27 27 groups.

28 28 We found sex differences in support for statement regarding two statements: support for free  
29 29 cessation treatment among current smokers, and support for standard treatment for patients with  
30 30 physical disorders among the whole sample. Each time men had lower odds of supporting said  
31 31 healthcare policies. Whether disease concepts, including concepts of addiction,<sup>31</sup> play a role in these  
32 32 differences needs to be explored further, ideally using both survey data and in-depth qualitative  
33 33 research.

1  
2 1 Respondents who indicated a high motivation to quit seem to be more supportive of training  
3 2 healthcare professionals to advise smokers on how to quit tobacco. In light of the fact that the  
4 3 majority of quit attempts in Germany occur unaided,<sup>3</sup> this result highlights the need for the  
5 4 integration of such training into health professional education in Germany.

6  
7  
8  
9 5 Compared with other European countries, tobacco cessation treatment is not well integrated into  
10 6 healthcare in Germany, despite knowledge about the burden of disease caused by tobacco use. The  
11 7 Germany SimSmoke study estimated that over 140,000 lives could be saved between 2020 and 2040  
12 8 if cessation treatment were provided for free and comprehensively,<sup>32</sup> indicating a potential for better  
13 9 public health in Germany were such policies implemented.

14  
15  
16  
17  
18  
19 10 This study has some limitations. We were only able to pose the healthcare policy support questions  
20 11 in one wave of the DEBRA survey due to resource constraints. It would be interesting to repeat the  
21 12 assessment in the future to gain insights into temporal trends and sensitivity of public acceptance in  
22 13 light of actual healthcare policy changes.

23  
24  
25  
26 14 As the proposed healthcare policies would directly affect healthcare professionals in their training  
27 15 and work, it would be useful to not only assess public support, but also healthcare professionals'  
28 16 support towards these measures. As DEBRA is a nationally representative sample, however, findings  
29 17 give good insights into the overall population. Research with a sample of healthcare professionals  
30 18 could complement our national study.

31  
32  
33  
34  
35  
36 19 The policies assessed here are only hypothetical. We are therefore unable to say whether public  
37 20 support would change in light of actual implementation. In addition, respondents were not asked  
38 21 about who would pay for free cessation treatment. Other studies have found that the public is willing  
39 22 to pay for effective tobacco control<sup>33</sup> however, this willingness to spend has its limits.

40  
41  
42  
43 23 Our findings help fill a knowledge gap on what changes to the tobacco cessation treatment system in  
44 24 Germany the country's population would agree to. Few studies have assessed public support for  
45 25 cessation treatment measures rather than tobacco control policies such as taxation or smokefree  
46 26 legislation. Information on public acceptance for specific tobacco treatment measures is even scarcer  
47 27 in Germany than for tobacco control. In Germany, DEBRA is one of only a few representative surveys  
48 28 targeting smoking and tobacco use behaviour,(e.g.,<sup>34</sup>) and is the only one providing both cross-  
49 29 sectional and longitudinal data on specific tobacco-related questions at 2 month intervals.<sup>17</sup>

50  
51  
52  
53  
54  
55 30 Making cessation treatment a part of standard care for patients with physical and mental health  
56 31 disorders is a practice that has already been successful elsewhere,<sup>35</sup> and that would be in line with  
57 32 the German clinical practice guidelines for the treatment of tobacco addiction.<sup>8, 9</sup> As such, these



1  
2 1 proposed healthcare policies are within the realm of the possible. Our findings show that offering  
3  
4 2 cessation treatment as standard care in Germany would be accepted by the public.

### 6 3 **Conclusions**

7  
8  
9 4 Public support for integrating tobacco cessation treatment into the health system is high in Germany,  
10  
11 5 in both smokers and non- or ex-smokers. Non-smokers were more supportive than current smokers  
12  
13 6 but it is encouraging that the difference regarding the level of support between these two groups is  
14  
15 7 small. Socio-demographic characteristics were not consistently associated with public acceptance.  
16  
17 8 Offering tobacco cessation treatment to patients with physical diseases was generally more accepted  
18  
19 9 than for patients with mental disorders. Providing cessation treatment offers to all smoking patients  
20  
21 10 or, as a bare minimum, to those presenting with chronic disorders could be an accepted way forward  
22  
23 11 in German tobacco control.

24 12

### 25 13 **ABBREVIATIONS**

26 14 GP = General practitioner

27 15 CI = Confidence interval

28 16 DEBRA = German Study on Tobacco Use (In German: "Deutsche Befragung zum Rauchverhalten")

29 17 FCTC = Framework Convention on Tobacco Control

30 18 MTSS = Motivation to Stop Scale (In German: MRS = "Motivation zum Rauchstopp Skala")

31 19 NCSCT = National Centre for Smoking Cessation and Training

32 20 NRT = Nicotine replacement therapy

33 21 OR = Odds ratio

34 22 QOF = Quality Outcome Framework

35 23 SD = Standard deviation

36 24 SES = Socioeconomic status

37 25 STS = Smoking Toolkit Study

38 26 WHO = World Health Organization

39 27

### 40 28 **DECLARATIONS**

#### 41 29 **Acknowledgements**

42 30 The authors would like to thank: Professor Robert West for support with the DEBRA study design;  
43 31 Kantar Health (Constanze Cholmakow-Bodechtel and Linda Scharf) for data collection; and Yekaterina  
44 32 Pashutina for her support with table entries.

45 33

#### 46 34 **Consent to participate**

1  
2 1 The fieldwork is conducted by the market research institute Kantar Health Munich, Germany. The  
3  
4 2 interviewers from Kantar Health make sure that all participants give oral informed consent. This  
5  
6 3 method of consent has been also approved by the ethics committee.  
7  
8 4

#### 5 **Data sharing statement**

6 All relevant data are within the paper. The data underlying this study are third-party data  
7 (deidentified participant data, syntax of statistical analyses) and are available to all researchers on  
8 reasonable request from the principal investigator of the DEBRA study (Prof. Dr. Daniel Kotz:  
9 daniel.kotz@med.uni-duesseldorf.de), up to 10 years following the data collection.  
10

#### 11 **Patient and Public Involvement statement**

12 Patients were not involved in this study.  
13

#### 14 **Funding**

15 This work was supported by the Ministry for Culture and Science of the German Federal State of  
16 North Rhine-Westphalia ("NRW-Rückkehrprogramm") who had no involvement in the design of the  
17 study, the collection, analysis, and interpretation of data, or in the writing of the manuscript.  
18

#### 19 **Competing interests**

20 SK and MB have no conflict of interest to declare. JB has received unrestricted research funding from  
21 Pfizer, who manufacture smoking cessation medications. LS has received honoraria for talks, an  
22 unrestricted research grant and travel expenses to attend meetings and workshops from Pfizer, and  
23 has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care  
24 companies. DK received an unrestricted grant from Pfizer in 2009 for an investigator-initiated trial on  
25 the effectiveness of practice nurse counselling and varenicline for smoking cessation in primary care  
26 (Dutch Trial Register NTR3067). All authors declare no financial links with tobacco companies or e-  
27 cigarette manufacturers or their representatives.  
28

#### 29 **Author contributions**

30 SK coordinates the DEBRA study, drafted the manuscript, analysed and interpreted the data. MB co-  
31 wrote the manuscript and interpreted the data. DK conceived the DEBRA study, contributed to the  
32 study design for the policy question analysis, and contributed to the writing of the manuscript. LS  
33 and JB work for the English Smoking Toolkit Study with which DEBRA is closely aligned, and  
34 contributed to the study design as well as to the writing of the manuscript. All named authors  
35 contributed substantially to the manuscript and agreed on its final version.

## REFERENCES

1. WHO. WHO report on the global tobacco epidemic. Warning about the dangers of tobacco 2011. [http://www.who.int/tobacco/global\\_report/2011/en/](http://www.who.int/tobacco/global_report/2011/en/). Accessed 25.06.2018.
2. European Commission. Special Eurobarometer 458. Attitudes of Europeans towards tobacco and electronic cigarettes. 2017. [https://data.europa.eu/euodp/en/data/dataset/S2146\\_87\\_1\\_458\\_ENG](https://data.europa.eu/euodp/en/data/dataset/S2146_87_1_458_ENG). Accessed 15.04.2019.
3. Kotz D, Böckmann M, Kastaun S. The Use of Tobacco, E-Cigarettes, and Methods to Quit Smoking in Germany. A representative study using 6 waves of data over 12 months (the DEBRA study). *Dtsch Arztebl Int* 2018;115:235-42.
4. Kuntz B, Zeiher J, Hoebel J, et al. Social inequalities, Smoking and Health [Soziale Ungleichheit, Rauchen und Gesundheit]. *Suchttherapie* 2016;17:115-23.
5. Royal College of Physicians, Royal College of Psychiatrists. Smoking and mental health. Royal College of Psychiatrists Council Report CR178. 2013. <https://www.rcplondon.ac.uk/projects/outputs/smoking-and-mental-health>. Accessed 14.04.2019.
6. Framework Convention on Tobacco Control (FCTC) Article 14 Guidelines. 2010. [http://www.who.int/fctc/guidelines/adopted/article\\_14/en/](http://www.who.int/fctc/guidelines/adopted/article_14/en/). Accessed 25.03.2019.
7. The Tobacco Control Scale 2016 in Europe. A report of the Association of the European Cancer Leagues. 2016. <https://www.tobaccocontrolscale.org/>. Accessed 15.04.2019.
8. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) S3 Guideline "Screening, Diagnostics, and Treatment of Harmful and Addictive Tobacco Use" [S3-Leitlinie "Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsums"]. AWMF-Register Nr. 076-006. 2015. <http://www.awmf.org/leitlinien/detail/II/076-006.html>. Accessed 15.04.2019.
9. Andreas S, Batra A, Behr J, et al. Smoking cessation in patients with COPD. [Tabakentwöhnung bei COPD S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.]. *Pneumologie* 2014;68:237-58.
10. Twardella D, Brenner H. Lack of training as a central barrier to the promotion of smoking cessation: a survey among general practitioners in Germany. *Eur J Public Health* 2005;15:140-5.
11. Kastaun S, Kotz D. Brief physician advice for smoking cessation: Results of the DEBRA study [Ärztliche Kurzberatung zur Tabakentwöhnung – Ergebnisse der DEBRA Studie]. Online first 31.01.2019: <https://econtent.hogrefe.com/doi/abs/10.1024/0939-5911/a000574>. *SUCHT* 2019:1-8.
12. Brown J, West R, Angus C, et al. Comparison of brief interventions in primary care on smoking and excessive alcohol consumption: a population survey in England. *Br J Gen Pract* 2016;66:e1-e9.
13. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction* 2004;99:29-38.
14. Schumann A, John U, Thyrian JR, et al. Attitudes towards smoking policies and tobacco control measures in relation to smoking status and smoking behaviour. *Eur J Publ Health* 2006;16:513-19.
15. Keller S, Weimer-Hablitzel B, Kaluza G, et al. Attitudes towards smoking policy and smoking status [Einstellungen zur Raucherpolitik in Abhängigkeit vom aktuellen Raucherstatus]. *Z Med Psychol* 2002;11:177-84.
16. Schaller K, Braun S, Pötschke-Langer M. Success story protection from second-hand smoke exposure in Germany: Increased public support for legislative measures [Erfolgsgeschichte Nichtraucherschutz in Deutschland: Steigende Unterstützung in der Bevölkerung für gesetzliche Maßnahmen]. *Gesundheitsmonitor NewsI* 2014:1-9.

- 1  
2 1 17. Kastaun S, Brown J, Brose LS, et al. Study protocol of the German Study on Tobacco Use  
3 2 (DEBRA): a national household survey of smoking behaviour and cessation. *BMC Public*  
4 3 *Health* 2017;17:378.  
5 4 18. Boeckmann M, Kotz D, Shahab L, et al. German Public Support for Tobacco Control Policy  
6 5 Measures: Results from the German Study on Tobacco Use (DEBRA), a Representative  
7 6 National Survey. *Int J Environ Res Public Health* 2018;15.  
8 7 19. Kotz D, Brown J, West R. Predictive validity of the Motivation To Stop Scale (MTSS): A single-  
9 8 item measure of motivation to stop smoking. *Drug & Alcohol Depend*;128:15-19.  
10 9 20. Fidler JA, Shahab L, West O, et al. 'The smoking toolkit study': a national study of smoking  
11 10 and smoking cessation in England. *BMC Public Health* 2011;11:479.  
12 11 21. Bowling A. Mode of questionnaire administration can have serious effects on data quality. *J*  
13 12 *Public Health* 2005;27:281-91.  
14 13 22. Thomson G, Wilson N, Collins D, et al. Attitudes to smoke-free outdoor regulations in the  
15 14 USA and Canada: a review of 89 surveys. *Tob Control* 2016;25:506-16.  
16 15 23. Li Q, Hyland A, O'Connor R, et al. Support for smoke-free policies among smokers and non-  
17 16 smokers in six cities in China: ITC China Survey. *Tob Control* 2010;19 Suppl 2:i40-6.  
18 17 24. Hoebel J, Kuntz B, Kroll LE, et al. Trends in Absolute and Relative Educational Inequalities in  
19 18 Adult Smoking Since the Early 2000s: The Case of Germany. *Nicotine Tob Res* 2018;20:295-  
20 19 302.  
21 20 25. Lampert T, von der Lippe E, Mütters S. Prevalence of smoking in the adult population of  
22 21 Germany [Verbreitung des Rauchens in der Erwachsenenbevölkerung in Deutschland].  
23 22 *Bundesgesundhbl Gesundheitsforsch Gesundheitsschutz* 2013;56:802-08.  
24 23 26. Pinto-Meza A, Moneta MV, Alonso J, et al. Social inequalities in mental health: results from  
25 24 the EU contribution to the World Mental Health Surveys Initiative. *Soc Psychiatry Psychiatr*  
26 25 *Epidemiol* 2013;48:173-81.  
27 26 27. Mackenbach JP, Stirbu I, Roskam AJ, et al. Socioeconomic inequalities in health in 22  
28 27 European countries. *N Engl J Med* 2008;358:2468-81.  
29 28 28. Epping J, Muschik D, Geyer S. Social inequalities in the utilization of outpatient  
30 29 psychotherapy: analyses of registry data from German statutory health insurance. *Int J Equity*  
31 30 *Health* 2017;16:147.  
32 31 29. Sheals K, Tombor I, McNeill A, et al. A mixed-method systematic review and meta-analysis of  
33 32 mental health professionals' attitudes toward smoking and smoking cessation among people  
34 33 with mental illnesses. *Addiction* 2016;111:1536-53.  
35 34 30. Taylor G, McNeill A, Girling A, et al. Change in mental health after smoking cessation:  
36 35 systematic review and meta-analysis. *BMJ* 2014;348:g1151.  
37 36 31. Racine E, Sattler S, Escande A. Free Will and the Brain Disease Model of Addiction: The Not  
38 37 So Seductive Allure of Neuroscience and Its Modest Impact on the Attribution of Free Will to  
39 38 People with an Addiction. *Front Psychol* 2017;8:1850.  
40 39 32. Levy DT, Blackman K, Currie LM, et al. Germany SimSmoke: the effect of tobacco control  
41 40 policies on future smoking prevalence and smoking-attributable deaths in Germany. *Nicotine*  
42 41 *Tob Res* 2013;15:465-73.  
43 42 33. Sanders AE, Slade GD, Ranney LM, et al. Valuation of tobacco control policies by the public in  
44 43 North Carolina: comparing perceived benefit with projected cost of implementation. *N C*  
45 44 *Med J* 2012;73:439-47.  
46 45 34. Piontek D, Kraus L, Matos EGd, et al. Epidemiological Survey of Substance Abuse 2015 [Der  
47 46 Epidemiologische Suchtsurvey 2015]. *SUCHT* 2016;62:259-69.  
48 47 35. Szatkowski L, Aveyard P. Provision of smoking cessation support in UK primary care: impact  
49 48 of the 2012 QOF revision. *The British Journal of General Practice* 2016;66:e10-e15.  
50  
51  
52  
53  
54  
55  
56 49  
57  
58  
59  
60

**Table 1** Baseline characteristics of the total sample, and by smoking status (unweighted data)<sup>a</sup>

	Total sample (N = 2,062; 100%)	Current smoker (N = 586; 28.4%)	Ex-smoker (N = 369; 17.9%)	Never smoker (N = 1,107; 53.7%)
Age, years (mean $\pm$ SD)	51.8 $\pm$ 19.8	47.1 $\pm$ 17.2	58.4 $\pm$ 17.5	52.1 $\pm$ 21.1
Sex				
Female	1,070 (51.9%)	271 (46.2%)	143 (38.8%)	656 (59.3%)
Male	992 (48.1%)	315 (53.8%)	226 (61.2%)	451 (40.7%)
Education <sup>b</sup>				
High school equiv.	479 (23.2%)	110 (19.2%)	85 (23.2%)	284 (27.4%)
Adv. tech. college equiv.	133 (6.5%)	28 (4.9%)	30 (8.2%)	75 (7.2%)
Secondary school equiv.	686 (33.3%)	230 (40.1%)	116 (31.7%)	340 (32.8%)
Junior high school equiv.	646 (31.3%)	193 (33.6%)	130 (35.5%)	323 (31.1%)
No qualification	33 (1.6%)	13 (2.3%)	5 (1.4%)	15 (1.4.5%)
Household income				
>€5000 /per month	134 (6.5%)	26 (4.4%)	27 (7.3%)	81 (7.3%)
€4000-5000/per month	128 (6.2%)	31 (5.3%)	24 (6.5%)	73 (6.6%)
€3000-4000/per month	369 (17.9%)	96 (16.4%)	67 (18.2%)	206 (18.6%)
€2000-3000/per month	557 (27.0%)	164 (28.0%)	106 (28.7%)	287 (25.9%)
€1000-2000/per month	638 (30.9%)	173 (29.5%)	117 (31.7%)	348 (31.4%)
< €1,000/per month	236 (11.4%)	96 (16.4%)	28 (7.6%)	112 (10.1%)

<sup>a</sup>Baseline characteristics of the sample have also been published elsewhere<sup>18</sup> under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited: CC BY 4.0. Data are presented as number (% within row), unless otherwise stated. <sup>b</sup>German equivalents to education levels listed in table from highest to lowest: high school equivalent = "Allgemeine Hochschulreife," advanced technical college equivalent = "Fachhochschulreife," secondary school equivalent = "Realschulabschluss," junior high school equivalent = "Hauptschulabschluss."

**Table 2** Smoking characteristics of current smokers (unweighted data)

	Current smokers only (N = 586)
Cigarettes smoked per day (mean±SD)	15.3 ± 9.0
Made at least one quit attempt last year	140 (23.9%)
Motivation to stop smoking <sup>17</sup>	
Don't want to stop smoking	268 (45.7%)
Should stop but don't really want to	139 (23.7%)
Want to stop but haven't thought about when	52 (8.9%)
Want to stop but haven't decided when	51 (8.7%)
Really want to stop and hope to soon	43 (7.3%)
Really want to stop and intend to in the next 3 months	7 (1.2%)
Really want to stop and intend to in the next month	6 (1.0%)

Data are presented as number (%), unless otherwise stated.

**Table 3** Multivariable associations with support for the proposed healthcare policies in the total sample (N = 2,062), and in current smokers (N = 586)

	1) Every smoker gets cessation treatment for free	2) Training all healthcare professionals to advise smokers	3) Cessation support as standard care for smokers (physical diseases)	4) Cessation support as standard care for smokers (mental illness)
Smoking status				
Current smoker (ref.)	1	1	1	1
Ex-smoker	0.88 (0.67-1.16)	1.43 (1.07-1.92)*	1.37 (1.00-1.88)	1.19 (0.89-1.58)
Never smoker	0.88 (0.71-1.09)	1.43 (1.14-1.79)**	1.05 (0.83-1.33)	1.39 (1.11-1.73)**
Age, 10-year units <sup>a</sup>	1.01 (0.96-1.06)	1.05 (1.00-1.11)	1.06 (1.00-1.13)*	1.05 (1.00-1.11)
Sex				
Female (ref.)	1	1	1	1
Male	0.80 (0.66-0.97)*	0.83 (0.68-1.01)	0.74 (0.60-0.91)**	0.91 (0.75-1.10)
Education <sup>b</sup>				
High school equiv. (ref.)	1	1	1	1
Adv. tech. college equiv.	1.50 (1.00-2.24)*	1.16 (0.76-1.77)	1.21 (0.77-1.92)	1.41 (0.93-2.13)
Secondary school equiv.	1.34 (1.05-1.72)*	1.15 (0.88-1.49)	1.02 (0.77-1.34)	1.06 (0.82-1.37)
Junior high school equiv.	1.36 (1.03-1.79)*	0.99 (0.75-1.32)	0.93 (0.69-1.26)	1.23 (0.93-1.63)
No qualification	1.07 (0.49-2.34)	1.68 (0.69-4.11)	1.19 (0.49-2.91)	0.86 (0.39-1.91)
Household income				
€>5000/per month (ref.)	1	1	1	1
€4000-5000/per month	0.99 (0.60-1.64)	0.70 (0.42-1.19)	1.23 (0.69-2.19)	1.32 (0.79-2.21)
€3000-4000/per month	1.04 (0.69-1.58)	0.88 (0.56-1.36)	1.03 (0.65-1.165)	1.59 (1.04-2.43)*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

€2000-3000/per month	0.92 (0.62-1.38)	0.87 (0.57-1.33)	0.84 (0.54-1.32)	1.39 (0.92-2.10)
€1000-2000/per month	1.02 (0.68-1.53)	0.91 (0.59-1.40)	1.05 (0.67-1.64)	1.56 (1.03-2.37)*
< €1,000/per month	1.53 (0.97-2.43)	1.10 (0.67-1.78)	1.22 (0.73-2.04)	2.07 (1.29-3.31)**

**Current smokers only (N = 586)**

Cigarettes smoked/day, number <sup>c</sup>	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)
Quit attempt last year (yes/no)				
Yes, attempt to quit (ref.)	1	1	1	1
No, attempt to quit	0.80 (0.51-1.26)	0.70 (0.44-1.11)	0.91 (0.56-1.48)	0.84 (0.54-1.32)
Motivation to stop smoking (MRS) <sup>3</sup>	1.00 (0.87-1.14)	1.20 (1.04-1.40)*	1.14 (0.98-1.33)	0.95 (0.83-1.08)

Data are presented as adjusted OR (95% confidence interval around OR). Ref. = reference group. \*p<0.05; \*\*p<0.01. <sup>a</sup>continuous variable: age units are based on DEBRA study participation eligibility (14 years and older): 14-23; 24-33; 34-43; 44-53; 54-63; 64-73; 74-83; 84-93; 94-103, <sup>b</sup>German equivalents to education levels listed in table from highest to lowest: high school equivalent = "Allgemeine Hochschulreife," advanced technical college equivalent = "Fachhochschulreife," secondary school equivalent = "Realschulabschluss," junior high school equivalent = "Hauptschulabschluss", <sup>c</sup>continuous variable (MRS: increasing from 1 "don't want to top" to 7 "really want to stop, intend to in the next month").




### Figure Legends

**Figure 1** Proportion (with 95% confidence interval) of public support for healthcare policies (N=2,062 respondents, weighted data).

**Figure 2** Proportion (with 95% confidence interval) of support for healthcare policies in the subsample of current smokers (N=586 respondents, weighted data).

### Additional files


Additional file 1: Supplementary Table1\_DEBRA\_BMJopen.pdf (Content: Results of multivariable associations with support for the proposed healthcare policy in never- and ex-smokers (N = 1,476)).



**Figure 1** Proportion (with 95% confidence interval) of public support for healthcare policies (N=2,062 respondents, weighted data).

165x107mm (600 x 600 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 2** Proportion (with 95% confidence interval) of support for healthcare policies in the subsample of current smokers (N=586 respondents, weighted data).

185x104mm (600 x 600 DPI)

**Additional Table 1** Multivariable associations with support for the proposed healthcare policies in never- and ex-smokers (N = 1,476)

	<b>1) Every smoker gets cessation treatment for free</b>	<b>2) Training all healthcare professionals to advise smokers</b>	<b>3) Cessation support as standard care for smokers (physical diseases)</b>	<b>4) Cessation support as standard care for smokers (mental diseases)</b>
Age, 10-year units <sup>a</sup>	0.99 (0.93-1.05)	1.05 (0.99-1.12)	1.08 (1.01-1.16)*	1.04 (0.98-1.11)
Sex				
Female (ref.)	1	1	1	1
Male	0.90 (0.72-1.12)	0.90 (0.71-1.14)	0.82 (0.64-1.05)	0.97 (0.78-1.23)
Education <sup>†</sup>				
High school equiv. (ref.)	1	1	1	1
Advanced technical college equiv.	1.50 (0.95-2.36)	1.14 (0.70-1.83)	1.08 (0.65-1.82)	1.44 (0.89-2.32)
Secondary school equiv.	1.36 (1.01-1.83)*	1.44 (1.04-1.94)	1.06 (0.76-1.48)	1.07 (0.79-1.46)
Junior high school equiv.	1.42 (1.03-1.97)*	1.05 (0.75-1.49)	0.86 (0.60-1.24)	1.15 (0.82-1.61)
No qualification	0.54 (0.19-1.58)	1.03 (0.34-3.08)	0.68 (0.23-2.03)	0.49 (0.17-1.38)
Household income				
€>5000/per month (ref.)	1	1	1	1
€4000-5000/per month	1.08 (0.62-1.91)	0.63 (0.34-1.16)	1.46 (0.75-2.85)	1.74 (0.95-3.16)
€3000-4000/per month	1.13 (0.70-1.80)	0.79 (0.47-1.31)	1.14 (0.67-1.93)	1.67 (1.03-2.72)*
€2000-3000/per month	1.03 (0.66-1.62)	0.76 (0.46-1.24)	0.88 (0.53-1.46)	1.42 (0.89-2.28)
€1000-2000/per month	1.00 (0.64-1.58)	0.82 (0.50-1.36)	1.09 (0.65-1.82)	1.70 (1.06-2.72)*
< €1,000/per month	1.62 (0.93-2.80)	1.16 (0.64-2.13)	1.65 (0.87-3.12)	2.09 (1.19-3.69)*

Data are presented as adjusted OR (95% confidence interval around OR). Ref. = reference group. \*p<0.05; \*\*p<0.01; <sup>a</sup>continuous variable, <sup>†</sup>German equivalents to education levels listed in table from highest to lowest: high school equivalent = "Allgemeine Hochschulreife," advanced technical college equivalent = "Fachhochschulreife," secondary school equivalent = "Realschulabschluss," junior high school equivalent = "Hauptschulabschluss." Age units are based on DEBRA study participation eligibility (14 and older): 14-23; 24-33; 34-43; 44-53; 54-63; 64-73; 74-83; 84-93; 94-103.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4ff.
Objectives	3	State specific objectives, including any prespecified hypotheses <sup>1</sup>	Exploratory design
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5/6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6/7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6/7
Bias	9	Describe any efforts to address potential sources of bias	6-8
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	6, 8
		(e) Describe any sensitivity analyses	-
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6,8,9
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9, Table 1 (17)
		(b) Indicate number of participants with missing data for each variable of interest	8
Outcome data	15*	Report numbers of outcome events or summary measures	9, Figure 1 and 2
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9,10, Table 3 (19)
		(b) Report category boundaries when continuous variables were categorized	Table 3 (19/20)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8,9,10
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	10,11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).